Kurt Miller
Disease Characteristics and Completion of Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer Treated With Radium-223 in an International Early Access Program
Saad F, Carles J, Seger M, Reeves J, Wirth M, Miller K, Nilsson S, O'Sullivan J, Keizman D, Heinrich D, Gillessen Sommer S, Heidenreich A. Disease Characteristics and Completion of Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer Treated With Radium-223 in an International Early Access Program. Clin Genitourin Cancer 2019; 17:348-355.e5.
31.05.2019Disease Characteristics and Completion of Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer Treated With Radium-223 in an International Early Access Program
31.05.2019Clin Genitourin Cancer 2019; 17:348-355.e5
Saad Fred, Carles Joan, Seger Monica, Reeves John, Wirth Manfred, Miller Kurt, Nilsson Sten, O'Sullivan Joe M, Keizman Daniel, Heinrich Daniel, Gillessen Sommer Silke, Heidenreich Axel
Radium-223 in asymptomatic patients with castration-resistant prostate cancer and bone metastases treated in an international early access program
Heidenreich A, Nilsson S, Seger M, Reeves J, Miller K, Wirth M, Carles J, O'Sullivan J, Keizman D, Heinrich D, Gillessen Sommer S, Saad F. Radium-223 in asymptomatic patients with castration-resistant prostate cancer and bone metastases treated in an international early access program. BMC cancer 2019; 19:12.
07.01.2019Radium-223 in asymptomatic patients with castration-resistant prostate cancer and bone metastases treated in an international early access program
07.01.2019BMC cancer 2019; 19:12
Heidenreich Axel, Nilsson Sten, Seger Monica, Reeves John, Miller Kurt, Wirth Manfred, Carles Joan, O'Sullivan Joe M, Keizman Daniel, Heinrich Daniel, Gillessen Sommer Silke, Saad Fred
Radium-223 and concomitant therapies in patients with metastatic castration-resistant prostate cancer: an international, early access, open-label, single-arm phase 3b trial
Saad F, O'Sullivan J, Federhofer J, Wirth M, Tucci M, Petrenciuc O, Nilsson S, Miller K, Lévy J, Gratt J, Heinrich D, Heidenreich A, Gillessen Sommer S, Carles J. Radium-223 and concomitant therapies in patients with metastatic castration-resistant prostate cancer: an international, early access, open-label, single-arm phase 3b trial. Lancet Oncol 2016; 17:1306-16.
26.07.2016Radium-223 and concomitant therapies in patients with metastatic castration-resistant prostate cancer: an international, early access, open-label, single-arm phase 3b trial
26.07.2016Lancet Oncol 2016; 17:1306-16
Saad Fred, O'Sullivan Joe M, Federhofer Judith, Wirth Manfred, Tucci Marcello, Petrenciuc Oana, Nilsson Sten, Miller Kurt, Lévy Jérémy, Gratt Jeremy, Heinrich Daniel, Heidenreich Axel, Gillessen Sommer Silke, Carles Joan
Achievements and Perspectives in Prostate Cancer Phase 3 Trials from Genitourinary Research Groups in Europe: Introducing the Prostate Cancer Consortium in Europe
Fizazi K, Wirth M, Wiegel T, Miller K, McDermott R, James N, Hamdy F, Gschwend J, Gillessen Sommer S, de Wit R, Culine S, Castellano D, Bellmunt J, Ahlgren G, Abrahamsson P, Tombal B. Achievements and Perspectives in Prostate Cancer Phase 3 Trials from Genitourinary Research Groups in Europe: Introducing the Prostate Cancer Consortium in Europe. Eur Urol 2014
10.09.2014Achievements and Perspectives in Prostate Cancer Phase 3 Trials from Genitourinary Research Groups in Europe: Introducing the Prostate Cancer Consortium in Europe
10.09.2014Eur Urol 2014
Fizazi Karim, Wirth Manfred, Wiegel Thomas, Miller Kurt, McDermott Raymond, James Nicholas, Hamdy Freddie, Gschwend Juergen E, Gillessen Sommer Silke, de Wit Ronald, Culine Stéphane, Castellano Daniel, Bellmunt Joaquim, Ahlgren Goran, Abrahamsson Per-Anders, Tombal Bertrand